Showing results (51-60 of 197) with videos related to
Sort By:
Pageof 20
Plos One|July 24, 2008
Substantial alterations of the cutaneous bacterial biota in psoriatic lesionsZhan Gao, Chi-hong Tseng, Bruce E Strober, et al.Immunotherapy|November 14, 2022
Deucravacitinib in moderate-to-severe psoriasisAlan Vu, Victoria Maloney, Kenneth B GordonSeminars in Cutaneous Medicine and Surgery|May 1, 2010
Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasisMona Gandhi, Eihab Alwawi, Kenneth B GordonImmunotherapy|October 4, 2019
Risankizumab in moderate-to-severe plaque psoriasisLinda Serrano, Victoria Maloney, Kenneth B GordonExpert Opinion on Biological Therapy|October 15, 2022
Anti-IL 23 biologics for the treatment of plaque psoriasisAlan Vu, Caden Ulschmid, Kenneth B GordonJAMA|August 25, 2011
Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trialsCaitriona Ryan, Craig L Leonardi, James G Krueger, et al.Journal of Drugs in Dermatology : JDD|November 9, 2012
Apremilast for discoid lupus erythematosus: results of a phase 2, open-label, single-arm, pilot studyAieska De Souza, Bruce E Strober, Joseph F Merola, et al.Dermatology and Therapy|December 4, 2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 2Bruce E Strober, Jennifer Clay Cather, David Cohen, et al.Dermatology and Therapy|December 4, 2012
A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1Bruce E Strober, Jennifer Clay Cather, David Cohen, et al.Archives of Dermatology|May 22, 2002
Biologic therapy for psoriasis: the new therapeutic frontierPrashant Singri, Dennis P West, Kenneth B GordonPageof 20